Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation (DBCOND0082577)
Identifiers
- Synonyms
- FLT3-Mutated Acute Myeloid Leukemia / FLT3 mutated AML
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT04691648 A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation Not Available Not Available recruiting NCT02752035 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy treatment 3 active_not_recruiting NCT03182244 A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation treatment 3 active_not_recruiting NCT03730012 A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) treatment 1 / 2 completed NCT05520567 A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia treatment 1 / 2 recruiting NCT02310321 A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. treatment 1 / 2 active_not_recruiting NCT02829840 Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) treatment 1 / 2 withdrawn NCT03114228 An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) Not Available Not Available no_longer_available NCT03591510 A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML treatment 2 recruiting